catalent.com

Catalent to Acquire Cell Therapy Manufacturing Assets from Bone Therapeutics

Catalent has signed an agreement with Bone Therapeutics to acquire its facility and manufacturing assets in Gosselies, Belgium.

‌

The facility, which is next to Catalent’s existing cell therapy site, will allow Catalent to expand its industry-leading cell therapy capabilities and advanced clinical and commercial supply, and create an integrated European center of excellence in cell therapy.

Read More

Catalent Launches OptiGel^® DR, a Delayed/Enteric Release Softgel

‌

The OptiGel^® DR technology allows softgel capsules to be formed by combining pectin, a naturally derived polysaccharide, with gelatin, eliminating the need for a separate capsule coating step.

Read More

Catalent in the News

Catalent is Proud to Support Many High-Profile COVID-19 Programs

‌

Catalent has been awarded more than 60 COVID-19-related compounds including antivirals, vaccines, diagnostics and treatments across our biologics, gene therapy, oral technologies, softgel and clinical supply businesses.

Learn More

CBS News Interviews Karen Flynn, President, Biologics and Chief Commercial Officer, Catalent

‌

In the interview, on CBS News “60 Minutes”, Ms. Flynn discusses Catalent's role in the vaccine manufacturing process and how various supply chain partners are working together to deliver COVID-19 vaccines at warp speed.

Watch the full segment here

Catalent and BrainStorm Cell Therapeutics Partner for the Manufacture of NurOwn^®

‌

NurOwn^® is BrainStorm’s autologous cellular therapy being investigated for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease or motor neuron disease.

Partnership with Catalent

‌

The partnership will support the development and manufacturing of Taysha’s gene therapies at Catalent’s Maryland-based gene therapy facilities.

Read More

Catalent Boosts Supply Chain Transparency in Response to COVID-19 Manufacturing Urgency

‌

During a fireside chat at the virtual BIO Investors Forum, Karen Flynn, President, Biologics and Chief Commercial Officer, Catalent, discussed the company’s supply chain response to COVID-19: “We need open dialog about industry needs, up and down the supply chain for planning purposes.”

Read the BioSpace write-up

Fierce Pharma Interview: Oral Drug Development Scale-up

‌

In an interview with Fierce Life Sciences, Jeremy Trochu, Vice President and General Manager of Pharmaceutical Development Services at Catalent, discusses the key factors to consider when planning the scale-up of an oral drug development program.

Read More

DCAT Women Leaders in Pharma Interview Series

‌

Karen Flynn, President, Biologics and Chief Commercial Officer at Catalent was recently interviewed in DCAT's Alliance for Industry Women Leaders in Pharma series. She gives advice on leadership, industry insights and why she chose a career in science.

Read the Interview

Join Our Experts at Live Virtual Events to Hear the Latest on COVID-19 and

Technology Development Programs

Virtual Conference | Manufacturing Chemist Live | November 10-11

‌

Christopher Harrison, Director of Manufacturing Operations, Catalent will discuss some of the key issues to consider when planning for the scale-up of a small molecule development program, with a focus on highly potent drugs.

‌

Virtual Congress | 2020 Bio/Pharma Virtual Congress | November 11

‌

Lisa Caralli, Director, Science and Technology, Catalent will discuss data-driven approaches to early development including PBPK modeling, parallel formulation screening, API-sparing techniques and optimal early dosing strategies that will help avoid development pitfalls and de-risk path to clinic.

‌

Webinar | Discover the Latest Funding, Drug Development and Clinical Solutions Strategies | November 11

‌

This webcast is specifically designed for pharmaceutical and biotech consultants, and early stage development partners. Experts in early drug development will present their insights to help your clients get their molecules from preclinical to Phase 1 studies.

Virtual Symposium | PBSS-CLSA Symposium: The Drug Discovery and Development Journey of Polivy™ | November 13

‌

Penelope Drake, Ph.D., Director of R&D, Catalent Biologics, will present on the demonstrated success of SMARTag^® site-specific bioconjugation technology across several therapeutic modalities.

Webinar | Optimizing Direct-to-Patient Clinical Supply for Decentralized Clinical Trials | November 19

‌

Learn about the benefits of direct-to-patient clinical supply and how sponsors can implement this model into their decentralized trials. Catalent’s Nicole Gray will appear as a featured panelist.

‌

Webinar | Early Drug Development: Strategy and Solution | November 26

‌

This webinar will focus on the key considerations for transitioning small molecules from preclinical to clinical development.

A Catalyst in Drug Development

William Wei Lim Chin, Ph.D.

Global Scientific Affairs Manager, Science & Technology, Eberbach, Germany

Dr. Chin is a biomedical and pharmaceutical scientist, he received his doctorate degree from the Department of Pharmacy at the National University of Singapore. In his current role at Catalent’s Eberbach, Germany, facility he is responsible for developing scientific content, designing tactics for scientific communications, ensuring technical accuracy and validity of key messaging across all business units. Access Dr. Chin’s extensive research and peer-reviewed articles on oral delivery, pediatric drug formulation and more.

Access His Works

Top Content

Biologics

‌

Webinar: “Disease Prevention & Control Summit 2020: Manufacturing Drugs & Vaccines Panels” - Originally presented at the virtual Disease Prevention & Control Summit, this panel-style webinar features experts from AstraZeneca, Translate Bio, and Catalent Biologics. Participants discussed the risks and challenges associated with pandemic drug manufacture.
Webinar: “The Faster Path to Self-Administration: Moving from Pre-Filled Syringe to Auto-Injector” – Experts from Ypsomed and Catalent Biologics discuss strategies for integrated pre-filled syringe manufacturing and auto-injector assembly to accelerate timelines and more.
Article: “Drug Product Process Development: Ensuring a Consistent, High-quality Biologic” - In this Q&A, Dhaval Patel, Manager, Manufacturing Technology, Drug Product, Catalent Biologics shares perspectives on overcoming process development challenges with new biological entities and biosimilars, and what to expect from the development and manufacturing partner during the drug product process development phase.

Cell & Gene Therapy

‌

Webinar: “Technology Integrators in Cell and Gene Therapy: Powering Innovation” - Julien Meissonnier, Catalent’s Vice President and Chief Scientific Officer, discusses innovative approaches, technology disruptors, and more.
Article: “Contract Manufacturer Sets Up for Fill-and-Finish Next-Generation Therapies” - Jef Pinxteren, Ph.D., Director of Process and Analytical Development, Catalent Cell Therapy, discusses the company’s fill-finish capabilities in Genetic Engineering & Biotechnology News.
Webinar: “Overcoming Scalability Challenges with Autologous Therapies” - Professor Gerhard Bauer discusses the current challenges associated with autologous therapies and Dr. James Crutchley speaks to the various solutions available for commercial scale-up of advanced therapeutics.

Clinical Supply Services

‌

eBook: “Early Drug Development Strategies for Clinical Success” - The optimal time to begin planning a clinical supply strategy is while the study drug is still at an early stage of development. This eBook discusses how to navigate individual study complexities and to mitigate risk.
Infographic: “Designing an Optimal Asia-Pacific Clinical Supply Chain – What Every Sponsor Should Know” - Learn how to navigate the complex clinical supply distribution landscape within this important growth region.
eBook: “Primary Packaging” - Download the eBook to get expert insights on the best packaging strategies to solve stability and blinding concerns, address country-specific regulatory requirements, overcome kit configuration challenges and support patient-centered design.

Oral Drug Delivery

‌

eBook: “Next-Generation Orphan Drug Delivery” - Learn more about mastering new drug delivery technologies, the ways for companies to enable their drugs to get to market faster and the future for orphan drugs.
Webinar: “Reducing Risks in Early Drug Development: From Drug Candidate to Phase 1 Clinical Testing” - Learn the key testing strategies that can help you determine the potential of your molecule and identify the red flags in development that indicate the need for additional studies
Article: "Drug Delivery Roundtable" - Catalent’s Susan Banbury, Head of Zydis^® Formulation, and Stephen Carino, Manager, Early Development, joined other industry representatives in a recent American Pharmaceutical Review roundtable.

Consumer Health

‌

Webinar: “Innovations in Nutritional Supplements: Catalent’s Newest Delivery Technology, OptiGel^® DR” - In this webinar, Catalent introduces its latest innovation: OptiGel^® DR delayed release softgel technology. This new technology is applicable to a wide range of ingredients and formulations.
eBook: “Active Aging - Opportunities to Support Health-Minded Consumers with Improved Nutritional Supplements” - Learn about the move to focus on ‘health’ rather than ‘years’, and gain insights into nutrition that can help support active lifestyles.
Infographic: “How OTC Monograph Affects You” - Learn about how changes in OTC monograph reform are opening up new product opportunities.

We Are Hiring. Join Us!

Catalent ignites the development of their future leaders by continuously investing in their employees and creating an innovative environment to advance their potential. We are growing rapidly across sites in Bloomington, Indiana, Madison, Wisconsin, Winchester, Kentucky, and more.

‌

Visit www.catalent.com/careers for more information.

Every brand has a challenge. We have a solution.

Challenge Us

or call +1 877 891 9609 to speak with one of our experts today!

To unsubscribe or manage your subscriptions, please click here.

‌

For more information call +1-866-720-3148 or in Europe 00800 88 55 6178, email us at sales@catalent.com, or visit our website www.catalent.com. And to learn more about Career opportunities across our global network, visit www.catalent.com/careers.

Catalent Pharma Solutions respects your privacy.

Links to third party sites are provided as a convenience only. Catalent makes no representation or warranty about the technology, security or any content available at these sites. Links are not intended to imply Catalent's affiliation or endorsement of the website, its owner(s) or the content.